- Home
- BCDA vs ROMA Comparison
BCDA vs ROMA Comparison
Compare BCDA & ROMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ROMA
- Stock Information
- Founded
- BCDA N/A
- ROMA 2018
- Country
- BCDA United States
- ROMA Hong Kong
- Employees
- BCDA N/A
- ROMA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ROMA Savings Institutions
- Sector
- BCDA Health Care
- ROMA Finance
- Exchange
- BCDA Nasdaq
- ROMA Nasdaq
- Market Cap
- BCDA 11.3M
- ROMA 150.7M
- IPO Year
- BCDA N/A
- ROMA 2024
- Fundamental
- Price
- BCDA $1.54
- ROMA $3.15
- Analyst Decision
- BCDA Strong Buy
- ROMA
- Analyst Count
- BCDA 1
- ROMA 0
- Target Price
- BCDA $25.00
- ROMA N/A
- AVG Volume (30 Days)
- BCDA 94.6K
- ROMA 50.9K
- Earning Date
- BCDA 11-12-2025
- ROMA 09-25-2025
- Dividend Yield
- BCDA N/A
- ROMA N/A
- EPS Growth
- BCDA N/A
- ROMA N/A
- EPS
- BCDA N/A
- ROMA N/A
- Revenue
- BCDA N/A
- ROMA $1,568,345.00
- Revenue This Year
- BCDA N/A
- ROMA N/A
- Revenue Next Year
- BCDA N/A
- ROMA N/A
- P/E Ratio
- BCDA N/A
- ROMA N/A
- Revenue Growth
- BCDA N/A
- ROMA 23.21
- 52 Week Low
- BCDA $1.54
- ROMA $0.54
- 52 Week High
- BCDA $3.25
- ROMA $4.66
- Technical
- Relative Strength Index (RSI)
- BCDA 29.50
- ROMA 56.69
- Support Level
- BCDA $2.11
- ROMA $2.28
- Resistance Level
- BCDA $2.29
- ROMA $3.37
- Average True Range (ATR)
- BCDA 0.12
- ROMA 0.34
- MACD
- BCDA -0.04
- ROMA 0.11
- Stochastic Oscillator
- BCDA 0.66
- ROMA 84.63
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.